Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study.

Journal for immunotherapy of cancer - 1 Mar 2021

Ji Niannian, Mukherjee Neelam, Reyes Ryan M, Gelfond Jonathan, Javors Martin, Meeks Joshua J, McConkey David J, Shu Zhen-Ju, Ramamurthy Chethan, Dennett Ryan, Curiel Tyler J, Svatek Robert S

Abstract excerpt

BACKGROUND: Although intravesical BCG is the standard treatment of high-grade non-muscle invasive bladder cancer (NMIBC), response rates remain unsatisfactory. In preclinical models, rapamycin enhances BCG vaccine efficacy against tuberculosis and the killing capacity of γδ T cells, which are critical for BCG's antitumor effects. Here, we monitored immunity, safety, and tolerability of rapamycin combined with BCG...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adjuvants, Immunologic
Share to BCG Vaccine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Neoplasm Grading

Share to Sirolimus

Share to Tumor Microenvironment

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 33653802
DOI: 10.1136/jitc-2020-001941
PMCID: PMC7929866

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study.PMID 33653802Read ↗

Immunotherapy in Bladder Cancer: A Systematic Review of Clinical Trials and Therapeutic AdvancesSemantic proximity Read ↗

Intravesical BCG in patients with non-muscle invasive bladder cancer induces trained immunity and decreases respiratory infectionsSemantic proximity Read ↗

Microbial cancer immunotherapy reprograms hematopoiesis to enhance anti-tumor immunitySemantic proximity Read ↗

Differential effects of BCG-Russia and BCG-TICE on trained immunity: potential implications for bladder cancer immunotherapySemantic proximity Read ↗

Treatment of non-muscle invasive bladder cancer with Bacillus Calmette–Guerin (BCG): Biological markers and simulation studiesSemantic proximity Read ↗

Autophagy controls BCG-induced trained immunity and the response to intravesical BCG therapy for bladder cancer.Semantic proximity Read ↗

Anti-interleukin-10R1 monoclonal antibody in combination with bacillus Calmette--Guérin is protective against bladder cancer metastasis in a murine orthotopic tumour model and demonstrates systemic specific anti-tumour immunity.Semantic proximity Read ↗

Elevated T-cell exhaustion and urinary tumor DNA levels are associated with BCG failure in patients with non-muscle invasive bladder cancerSemantic proximity Read ↗

The Potential Antitumor Effects of Combining Intravesical Therapy with Recombinant Bacillus Calmette-Guérin and an Immune Checkpoint Inhibitor in Bladder CancerSemantic proximity Read ↗

Comparison of intravesical instillation of Bacille Calmette-Guérin and epirubicin: a randomized controlled trialSemantic proximity Read ↗

Macrophages drive the earliest anti-tumoral response to BCG therapy by directly killing bladder cancer through TNF signalingSemantic proximity Read ↗

Reactive arthritis after the intravesical instillation of BCG.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.